| Cat.No. | Name | Information |
|---|---|---|
| M10348 | 27-Hydroxycholesterol | 27-Hydroxycholesterol is a selective estrogen receptor modulator, and it is also an agonist of the liver X receptor. |
| M8508 | PHTPP | PHTPP is a selective estrogen receptor β (ERβ) full antagonist with 36-fold selectivity for ERβ over ERα. |
| M7871 | G15 | G15 is a high affinity and selective G-protein-coupled estrogen receptor (GPER/GPR30) antagonist with a Ki of 20 nM. |
| M7353 | Tamoxifen | Tamoxifen is an orally active, selective estrogen receptor partial agonist/antagonist. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively. |
| M5625 | Estradiol | Estradiol (17β-estradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol (17β-estradiol) can be used to construct animal models of chronic non-bacterial prostatitis. |
| M4836 | G-1 | G-1 is a potent and selective GPR30 receptor agonist (Ki = 11 nM, EC50 = 2 nM). |
| M4374 | Gypenoside-XVII | Gypenoside XVII is a novel phytoestrogens belonging to gypenosides, which can activate estrogen receptors. |
| M4368 | Kaempferol | Kaempferol is an inverse agonist of ERRα and ERRγ that inhibits estrogen receptor (ER α) expression in breast cancer cells and induces apoptosis by activating MEK-MAPK in glioblastoma cells and lung cancer cells. It can be used in breast cancer research. |
| M3371 | Estriol | Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells. |
| M2356 | 20-Hydroxyecdysone | 20-Hydroxyecdysone (Ecdysterone, 20E) is a naturally occurring ecdysteroid hormone which controls the ecdysis (moulting) and metamorphosis of arthropods. |
| M2174 | Calcitriol | Calcitriol is an Active metabolite of vitamin D3 that activates the vitamin D receptor. *The compound is unstable in solutions, freshly prepared is recommended |
| M1966 | Fulvestrant | Fulvestrant is a Estrogen receptor (ER) antagonist with IC50 of 0.094 nM. Fulvestrant can also induce autophagy and apoptosis, and has anti-tumor effect. |
| M55487 | L-Carnitine-d9 | L-Carnitine-d9 |
| M55468 | Hexestrol-d4 | Hexestrol-d4 |
| M54736 | hFSH-β-(33-53) TFA | hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells. |
| M45333 | FLTX1 | FLTX1 is a fluorescent tamoxifen derivative that specifically labels intracellular tamoxifen binding sites (estrogen receptors) under permeabilizing and non-permeabilizing conditions. In addition, FLTX1 exhibits potent anti-estrogenic activity of Tamoxifen in breast cancer cells.FLTX1 lacks estrogenic agonism in the uterus. |
| M30946 | (±)-Equol | (±)-Equol is the racemate of equol. (±)-equol exhibits EC50s of 200 and 74 nM for human ERα and ERβ, respectively. Equol is a metabolite of the soy isoflavones, daidzin and daidzein. |
| M29599 | Imlunestrant | Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC). |
| M28607 | Enclomiphene | Enclomiphene ((E)-Clomiphene) is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes. |
| M27811 | Endoxifen (Z-isomer) | Endoxifen Z-isomer is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα). Endoxifen inhibits hERG tail currents at 50 mV in a concentration-dependent manner with IC50 values of 1.6 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
